Publication Name	World Journal of Transplantation
Manuscript ID	108982
Country	Italy

Received	2025-04-27 05:39
Peer-Review Started	2025-04-27 05:39
To Make the First Decision
Return for Revision	2025-05-12 04:19
Revised	2025-05-26 08:02
Second Decision	2025-08-11 02:52
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-08-11 13:10
Articles in Press	2025-08-11 13:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-10-21 09:34
Publish the Manuscript Online	2025-11-19 05:57

ISSN	2220-3230 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Health Care Sciences & Services
Manuscript Type	Review
Article Title	Obinutuzumab in kidney transplantation: Past, present, and future
Manuscript Source	Invited Manuscript
All Author List	Evaldo Favi and Marika Morabito
Funding Agency and Grant Number
Corresponding Author	Evaldo Favi, MD, PhD, Department of General Surgery and Kidney Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza No. 28, Milan 20122, Lombardy, Italy. evaldofavi@gmail.com
Key Words	Obinutuzumab; Rituximab; Kidney transplantation; Desensitization; Antibody-mediated rejection; Glomerulopathies; Recurrence; Review
Core Tip	Antibody-mediated rejection and recurrent primary renal diseases remain major causes of kidney transplant loss. Obinutuzumab (OBI) is a type 2 anti-CD20 monoclonal antibody with enhanced peripheral and central B-cell depletion capacities compared to type 1 anti-CD20 monoclonal antibodies. Compared to other B-cell-targeted agents, OBI-induced B-cell depletion is marginally affected by complement function, primarily operating through antibody-dependent cell cytotoxicity, antibody-dependent cell phagocytosis, and direct cell death. These characteristics suggest that OBI might represent a game-changer in the management of highly sensitized transplant candidates, humoral rejection, and relapsing renal diseases. This review summarizes the current knowledge on OBI use in kidney transplantation.
Publish Date	2025-11-19 05:57
Citation	<p>Favi E, Morabito M. Obinutuzumab in kidney transplantation: Past, present, and future. <i>World J Transplant</i> 2025; 15(4): 108982</p>
URL	https://www.wjgnet.com/2220-3230/full/v15/i4/108982.htm
DOI	https://dx.doi.org/10.5500/wjt.v15.i4.108982

Full Article (PDF)	WJT-15-108982-with-cover.pdf
Manuscript File	108982_Auto_Edited_014257.docx
Answering Reviewers	108982-answering-reviewers.pdf
Audio Core Tip	108982-audio.m4a
Conflict-of-Interest Disclosure Form	108982-conflict-of-interest-statement.pdf
Copyright License Agreement	108982-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	108982-non-native-speakers.pdf
Peer-review Report	108982-peer-reviews.pdf
Scientific Misconduct Check	108982-scientific-misconduct-check.png
Scientific Editor Work List	108982-scientific-editor-work-list.pdf
CrossCheck Report	108982-crosscheck-report.pdf